RANI RANI THERAPEUTICS HLDGS INC revenue, earnings and financials

For the quarter ended June 30, 2026, RANI THERAPEUTICS HLDGS INC reported revenue of $1.71M, net income of −$7.39M and diluted EPS of −$0.04; over the last four quarters revenue was $4.88M and net income −$30.1M; for the fiscal year ended December 2025 revenue was $1.63M, up 58.9% on the year before.

RANI annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $1.63M, gross profit n/a, operating income −$38.3M, net income −$29.7M (margin -1817.1%), EPS −$0.45
• Fiscal year ended Dec 2024: revenue $1.03M, gross profit n/a, operating income −$53.3M, net income −$30.0M (margin -2920.0%), EPS −$1.05
• Fiscal year ended Dec 2023: revenue $0, gross profit n/a, operating income −$66.1M, net income −$34.0M (margin n/a), EPS −$1.33
• Fiscal year ended Dec 2022: revenue $0, gross profit n/a, operating income −$63.5M, net income −$30.6M (margin n/a), EPS −$1.28
• Fiscal year ended Dec 2021: revenue $2.72M, gross profit n/a, operating income −$51.6M, net income −$8.33M (margin -306.6%), EPS −$0.43

RANI quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $1.71M, net income −$7.39M, EPS −$0.04
• Quarter ended Mar 31, 2026: revenue $1.71M (up 893.0% year over year), net income −$7.03M, EPS −$0.04
• Quarter ended Dec 31, 2025 (from the annual report): revenue $1.46M (up 42.1% year over year), net income −$10.3M, EPS $0.07
• Quarter ended Sep 30, 2025: revenue $0, net income −$5.41M, EPS −$0.12
• Quarter ended Jun 30, 2025: revenue $0, net income −$6.69M, EPS −$0.18
• Quarter ended Mar 31, 2025: revenue $172K, net income −$7.26M, EPS −$0.22
• Quarter ended Dec 31, 2024 (from the annual report): revenue $1.03M, net income −$8.95M, EPS −$0.26
• Quarter ended Sep 30, 2024: revenue $0, net income −$6.78M, EPS −$0.24
• Quarter ended Jun 30, 2024: revenue $0, net income −$6.81M, EPS −$0.26
• Quarter ended Mar 31, 2024: revenue $0, net income −$7.48M, EPS −$0.29
• Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$7.10M, EPS −$0.27
• Quarter ended Sep 30, 2023: revenue n/a, net income −$9.20M, EPS −$0.36
• Quarter ended Jun 30, 2023: revenue n/a, net income −$9.30M, EPS −$0.37
• Quarter ended Mar 31, 2023: revenue n/a, net income −$8.37M, EPS −$0.33
• Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$8.79M, EPS −$2.21
• Quarter ended Sep 30, 2022: revenue $0, net income −$7.96M, EPS $0.33
• Quarter ended Jun 30, 2022: revenue $0 (down 100.0% year over year), net income −$7.62M, EPS $0.31
• Quarter ended Mar 31, 2022: revenue n/a, net income −$6.22M, EPS $0.29
• Quarter ended Dec 31, 2021 (from the annual report): revenue $0, net income $5.89M, EPS n/a
• Quarter ended Sep 30, 2021: revenue $0, net income −$3.14M, EPS −$0.16

RANI cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$18.7M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$35.5M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$51.2M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$46.5M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$32.2M, share buybacks n/a

RANI balance sheet

• Jun 30, 2026: cash $4.87M, total assets $60.8M, total liabilities $12.9M, shareholders' equity $39.2M
• Mar 31, 2026: cash $9.64M, total assets $51.9M, total liabilities $16.3M, shareholders' equity $28.4M
• Dec 31, 2025: cash $18.6M, total assets $58.6M, total liabilities $17.1M, shareholders' equity $33.0M, long-term debt $0
• Sep 30, 2025: cash $4.14M, total assets $10.1M, total liabilities $22.1M, shareholders' equity −$7.86M, long-term debt $0
• Jun 30, 2025: cash $10.2M, total assets $16.9M, total liabilities $26.1M, shareholders' equity −$5.58M, long-term debt $2.23M
• Mar 31, 2025: cash $10.1M, total assets $24.1M, total liabilities $29.5M, shareholders' equity −$3.06M, long-term debt $5.92M
• Dec 31, 2024: cash $3.76M, total assets $36.6M, total liabilities $33.1M, shareholders' equity $1.99M, long-term debt $9.61M
• Sep 30, 2024: cash $4.28M, total assets $43.5M, total liabilities $37.8M, shareholders' equity $3.12M, long-term debt $13.5M

What is RANI's revenue?

RANI THERAPEUTICS HLDGS INC reported $4.88M of revenue over its last four quarters, through June 30, 2026.

Is RANI profitable?

No. RANI THERAPEUTICS HLDGS INC lost $30.1M over the last four quarters.

What is RANI's EPS?

Diluted earnings per share over the last four quarters were −$0.13; −$0.04 in the latest quarter.

RANI ownership and insider trades · All stocks